Novartis hands off NASH drug to biotech collaborator, also plans to build new Basel production unit

After building up its work on NASH, Novartis is handing over one of its candidates to Boston Pharmaceuticals.

The private biotech, which didn’t discuss terms, gets the newly dubbed BOS-580, an FGF21 drug. And they get to launch a clinical foray into a field marked by multiple setbacks over the last 2 years.